Evidence map›Paper›PMID 41848091›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Pyroptosis-Inducing Engineered Microparticles for Cancer Immunotherapy.

Tianli Hao, Zihan Deng, Yufei Liu, Li Liu, Deqiang Deng, Muyang Yang, Yuanyuan Geng, Yao Sun, Beilei Yue, Jonathan F Lovell and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tianli HaoCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Zihan DengCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Yufei LiuCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Li LiuCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Deqiang DengNHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan, China.
Muyang YangNHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan, China.ORCID https://orcid.org/0009-0000-7340-1188
Yuanyuan GengCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Yao SunCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Beilei YueCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Jonathan F LovellDepartment of Biomedical Engineering, University At Buffalo, State University of New York, Buffalo, New York, USA.ORCID https://orcid.org/0000-0002-9052-884X
Yushuai LiuDepartment of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID https://orcid.org/0000-0003-4471-3662
Lisen LuNHC Key Laboratory of Tropical Disease Control, School of Life Sciences and Medical Technology, Hainan Medical University, Haikou, Hainan, China.
Honglin JinCollege of Biomedicine and Health and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.ORCID https://orcid.org/0000-0002-4398-9539

Funding

Fundamental Research Funds for the Central Universities 2662024JC005Hubei Provincial University Excellent Young and Middle-aged Scientific and Technological Innovation Team Plan Project T2024033National Natural Science Foundation of China 82272851 82473363 82402465
6 · The paper itself

Abstract

Pyroptosis, a form of immunogenic cell death, can remodel the immunosuppressive tumor microenvironment; however, its clinical translation is challenged by difficulties in targeted induction and biosafety concerns. In this study we discovered that geldanamycin (GA) can interacts specifically with arginine 207 (R207) in caspase‑3, and efficiently cleaved caspase-3, significantly inducing high-efficiency pyroptosis. Although high-dose GA promoted pyroptosis and antitumor immunity, physiological toxicity and the induction of resistance mediated by immune checkpoints including PD-L1 and CD47 limited therapeutic efficacy. To address this, we developed biomimetic dual-targeting microparticles(MPs)functionalized with anti-PD-L1 and anti-SIRPα nanobodies. This strategy synergized targeted pyroptosis induction with dual immune checkpoint blockade, achieving complete tumor regression, reduced physiological toxicity, and induced a potent effector immune response in murine cancer models, presenting a promising combinatorial approach for lung cancer immunotherapy.

Indexed as

ImmunotherapyNeoplasmsPyroptosisAnimalsCell Line, TumorFemaleHumansMiceTumor Microenvironmentbispecific adapterscancer immunotherapyGSDMEmicroparticlesnanobodiespyroptosis

Identifiers

PMID41848091
PMCPMC13587975

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.